SAN ANTONIO, Texas, U.S.A. (Jan. 16, 2013) — Patients who are started on antiretroviral therapy for HIV-1 infection within four months of estimated infection date — and who have higher counts of CD4+ T-cells at the initiation of therapy — demonstrate a stronger recovery of CD4+ T-cell counts than patients in whom therapy is started later, a new study shows.
The report, to be published Thursday in The New England Journal of Medicine, is co-authored by physicians of UT Medicine San Antonio and the University of California, San Diego and drew data from 468 patients followed in the San Diego Primary Infection Cohort. UT Medicine is the clinical practice of the School of Medicine at The University of Texas Health Science Center San Antonio. Co-authors are from the University of California, San Diego School of Medicine, the San Antonio Military Medical Center and Monash University in Australia.
Transient increase, then decline
In the four months after HIV-1 (human immunodeficiency virus type 1) infection, the immune system mounts an immune response toward a temporary restoration of CD4+ T-cell counts; CD4+ T-cells are specialized immune cells that are required to fight infections and are depleted during HIV infection. After this transient increase, the CD4+ count progressively declines. The study, funded by the National Institute of Allergy and Infectious Diseases and other sources, offers insight into the optimal timing of therapy.
"This study suggests greater urgency to start antiretroviral therapy earlier, when the most weapons in the immunity armamentarium are at the body's disposal," co-lead author Sunil K. Ahuja, M.D., said. Dr. Ahuja is professor of medicine, microbiology/immunology and biochemistry in the School of Medicine at the UT Health Science Center and director of the Veterans Administration Center for AIDS and HIV Infection, a national center within the South Texas Veterans Health Care System.
Observation of the transient restoration of CD4+ T-cell counts and their subsequent decline "raised the possibility that after acute infection there may be a narrow 'restorative time window' wherein the immune system could be strategically poised for recovery and that the likelihood and rate of recovery may be augmented by earlier initiation of potent antiretroviral therapy," co-lead author Susan J. Little, M.D., said. Dr. Little is professor of medicine at the University of California, San Diego School of Medicine.
Recovery of CD4+ T-cell counts to approximately normal levels of 900 or more cells per cubic milliliter was observed in 64 percent of participants who were put on antiretroviral therapy (ART) within four months of estimated date of infection, compared to 34 percent of participants in whom ART was initiated later.
"Even a fairly short deferral of ART after closure of this time window may come at the expense of compromised CD4+ T-cell recovery, irrespective of the CD4+ count at the time of treatment initiation," Dr. Ahuja said. "Further studies are needed to determine whether starting ART within the restorative time window promotes strategies that help fully reconstitute the immune system."
Timing of ART
In an accompanying editorial, Bruce Walker, M.D., and Martin Hirsch, M.D., of Harvard Medical School wrote: "The question of when to initiate ART remains a difficult one, particularly in resource-limited settings, but the studies in this issue of the Journal provide strong supportive evidence suggesting a benefit for early therapy." The authors noted that the study relies on a surrogate measure of disease progression, CD4+ T-cell count, rather than on clinical outcomes.
"Future studies of treatment even earlier in the course of infection may show additional benefits, and a population of such patients will be an important study group for eventual studies aimed at 'cure' of infection," Drs. Walker and Hirsch wrote.
Supported by the Veterans Affairs (VA) Center for AIDS and HIV Infection and VA Center for Personalized Medicine of the South Texas Veterans Health Care System and a MERIT grant (R37 AI046326) and a Clinical and Translational Science Award (UL1TR000149) from the National Institutes of Health (NIH) (all for the work at San Antonio) and by grants from the NIH (AI43638, AI69432, MH62512, AI74621, MH083552, AI077304, AI007384, AI080193, and AI096113), the International AIDS Vaccine Initiative (DMS0714991), and the California HIV/AIDS Research Program (RN07-SD-702) (all for the work at San Diego). Dr. Le was supported by a VA Career Development Award-2, Dr. Wright by an Early Career Fellowship from the National Health and Medical Research Council of Australia, and Dr. Ahuja by the Doris Duke Distinguished Clinical Scientist Award, a VA MERIT award, the Elizabeth Glaser Pediatric AIDS Foundation, the Burroughs Welcome Clinical Scientist Award in Translational Research, and the Senior Scholar Award from the Max and Minnie Tomerlin Voelcker Fund.
On the Web and social media
For current news from the UT Health Science Center San Antonio, please visit our news release website, like us on Facebook or follow us on Twitter.
About UT Medicine San Antonio
UT Medicine San Antonio is the clinical practice of the School of Medicine at the UT Health Science Center San Antonio. With more than 700 doctors – all School of Medicine faculty – UT Medicine is the largest medical practice in Central and South Texas. Expertise is in more than 100 medical specialties and subspecialties. Primary care doctors and specialists see patients in private practice at UT Medicine's flagship clinical home, the Medical Arts & Research Center (MARC), located at 8300 Floyd Curl Drive, San Antonio 78229. Most major health plans are accepted, and UT Medicine physicians also practice at several local and regional hospitals. Call (210) 450-9000 to schedule an appointment, or visit www.UTMedicine.org for a list of clinics and phone numbers.
About the South Texas Veterans Health Care System
The South Texas Veterans Health Care System (STVHCS) is comprised of two inpatient campuses: the Audie L. Murphy Memorial VA Hospital in San Antonio and the Kerrville VA Hospital in Kerrville. The STVHCS serves one of the largest primary service areas in the nation and is part of the VA Heart of Texas Veterans Integrated Service Network (VISN 17), with offices located in Arlington. With an FY12 budget for STVHCS of $605 million and more than 3,400 employees, South Texas provides health care services for 80,000 unique veterans. In FY12, STVHCS provided almost 1,271,843 outpatient visits to area veterans.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.